表紙
市場調査レポート

Vectura Group plc:製品パイプライン分析

Vectura Group Plc - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224639
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
Vectura Group plc:製品パイプライン分析 Vectura Group Plc - Product Pipeline Review - 2015
出版日: 2015年07月22日 ページ情報: 英文 37 Pages
概要

Vectura Group plc は、独自の肺送達技術を使った吸入薬を開発しています。高い処方技術力と装置で気管支肺疾患治療薬の開発、製造、商品化に取り組み、その技術を他企業にもライセンス供与しています。

development unit and laboratory facility in Cambridge. 当レポートでは、Vectura Group plc における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Vectura Group plc の基本情報

  • Vectura Group plc の概要
  • 主要情報
  • 企業情報

Vectura Group plc :R&Dの概要

  • 主な治療範囲

Vectura Group Plc:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Vectura Group Plc:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Vectura Group Plc:薬剤プロファイル

  • VR-475
  • VR-876
  • VR-096
  • VR-647
  • VR-736
  • Drug for Pulmonary Hypertension
  • VR-588

Vectura Group Plc:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Vectura Group Plc:最近のパイプライン動向

Vectura Group Plc:休止中のプロジェクト

Vectura Group Plc:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • VR-611

Vectura Group Plc:企業発表

Vectura Group Plc:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07277CDB

Summary

Global Markets Direct's, 'Vectura Group plc - Product Pipeline Review - 2015', provides an overview of the Vectura Group plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vectura Group plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vectura Group plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vectura Group plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vectura Group plc's pipeline products

Reasons to buy

  • Evaluate Vectura Group plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vectura Group plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vectura Group plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vectura Group plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vectura Group plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vectura Group plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vectura Group Plc Snapshot
    • Vectura Group Plc Overview
    • Key Information
    • Key Facts
  • Vectura Group Plc - Research and Development Overview
    • Key Therapeutic Areas
  • Vectura Group Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Vectura Group Plc - Pipeline Products Glance
    • Vectura Group Plc - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Vectura Group Plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Vectura Group Plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Vectura Group Plc - Drug Profiles
    • VR-475
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VR-876
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VR-096
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VR-647
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VR-736
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Pulmonary Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VR-588
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vectura Group Plc - Pipeline Analysis
    • Vectura Group Plc - Pipeline Products by Target
    • Vectura Group Plc - Pipeline Products by Route of Administration
    • Vectura Group Plc - Pipeline Products by Molecule Type
    • Vectura Group Plc - Pipeline Products by Mechanism of Action
  • Vectura Group Plc - Recent Pipeline Updates
  • Vectura Group Plc - Dormant Projects
  • Vectura Group Plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • VR-611
  • Vectura Group Plc - Company Statement
  • Vectura Group Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vectura Group Plc, Key Information
  • Vectura Group Plc, Key Facts
  • Vectura Group Plc - Pipeline by Indication, 2015
  • Vectura Group Plc - Pipeline by Stage of Development, 2015
  • Vectura Group Plc - Monotherapy Products in Pipeline, 2015
  • Vectura Group Plc - Partnered Products in Pipeline, 2015
  • Vectura Group Plc - Partnered Products/ Combination Treatment Modalities, 2015
  • Vectura Group Plc - Out-Licensed Products in Pipeline, 2015
  • Vectura Group Plc - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Vectura Group Plc - Phase III, 2015
  • Vectura Group Plc - Phase II, 2015
  • Vectura Group Plc - Phase I, 2015
  • Vectura Group Plc - Preclinical, 2015
  • Vectura Group Plc - Pipeline by Target, 2015
  • Vectura Group Plc - Pipeline by Route of Administration, 2015
  • Vectura Group Plc - Pipeline by Molecule Type, 2015
  • Vectura Group Plc - Pipeline Products by Mechanism of Action, 2015
  • Vectura Group Plc - Recent Pipeline Updates, 2015
  • Vectura Group Plc - Dormant Developmental Projects,2015
  • Vectura Group Plc - Discontinued Pipeline Products, 2015
  • Vectura Group Plc, Subsidiaries

List of Figures

  • Vectura Group Plc - Pipeline by Top 10 Indication, 2015
  • Vectura Group Plc - Pipeline by Stage of Development, 2015
  • Vectura Group Plc - Monotherapy Products in Pipeline, 2015
  • Vectura Group Plc - Partnered Products in Pipeline, 2015
  • Vectura Group Plc - Out-Licensed Products in Pipeline, 2015
  • Vectura Group Plc - Pipeline by Top 10 Target, 2015
  • Vectura Group Plc - Pipeline by Top 10 Route of Administration, 2015
  • Vectura Group Plc - Pipeline by Top 10 Molecule Type, 2015
  • Vectura Group Plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top